Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?

Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The National medical journal of India 2021-03, Vol.34 (2), p.90-91
Hauptverfasser: Gogia, Ajay, Mittal, Abhenil, Sharma, Atul, Sagiraju, Hari
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvant treatment
Analysis
Antimitotic agents
Antineoplastic agents
Breast cancer
Cancer
Epidermal growth factor
Monoclonal antibodies
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 91
container_issue 2
container_start_page 90
container_title The National medical journal of India
container_volume 34
creator Gogia, Ajay
Mittal, Abhenil
Sharma, Atul
Sagiraju, Hari
description
doi_str_mv 10.4103/0970-258X.326770
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_infotracmisc_A678269043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A678269043</galeid><sourcerecordid>A678269043</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428n-17fc0a97de759cf906743aed3e764ba5ba79ac724812c09b65d5428eb3b1f123</originalsourceid><addsrcrecordid>eNptkc2L1TAUxYsoOI7uXQYEd33mo21e3MgwjDPCgAtn4S7cprfTvGmTmqTzGLf-46Y80fdAssjlcH73wjlF8ZbRTcWo-ECVpCWvt983gjdS0mfF2V_p-dH8sngV447SRrCanRW_vg0-pLJbAiTrHYFutzyCSyQFiGn5uUzQkjRggPmJWEeGLDiCs-0wTDCS--D3aSA9mOQDCWhwXgdezj7aZB-RtAHzJmLAGQzxI7mBSGyKJNkJifETfnpdvOhhjPjmz39e3H2-uru8KW-_Xn-5vLgtTcW3rmSyNxSU7FDWyvSKNrISgJ1A2VQt1C1IBUbyasu4oapt6q7OILaiZT3j4rx4d1g7B_9jwZj0zi_B5Yua11IpXnGp_rnuYURtXe9zEmay0eiLRm55o2glsmvzH1d-HU7WeIe9zfoJ8P4IGBDGNEQ_Lmvo8dRID0YTfIwBez0HO0F40ozqtWm9VqnXKvWh6YxcH5C9H1PO-GFc9hj0hN2D8_sTrjzitKL6tH3xG80Qs3I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579924279</pqid></control><display><type>article</type><title>Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gogia, Ajay ; Mittal, Abhenil ; Sharma, Atul ; Sagiraju, Hari</creator><creatorcontrib>Gogia, Ajay ; Mittal, Abhenil ; Sharma, Atul ; Sagiraju, Hari</creatorcontrib><identifier>ISSN: 0970-258X</identifier><identifier>EISSN: 0970-258X</identifier><identifier>DOI: 10.4103/0970-258X.326770</identifier><language>eng</language><publisher>New Delhi: Wolters Kluwer India Pvt. Ltd</publisher><subject>Adjuvant treatment ; Analysis ; Antimitotic agents ; Antineoplastic agents ; Breast cancer ; Cancer ; Epidermal growth factor ; Monoclonal antibodies ; Targeted cancer therapy</subject><ispartof>The National medical journal of India, 2021-03, Vol.34 (2), p.90-91</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Gogia, Ajay</creatorcontrib><creatorcontrib>Mittal, Abhenil</creatorcontrib><creatorcontrib>Sharma, Atul</creatorcontrib><creatorcontrib>Sagiraju, Hari</creatorcontrib><title>Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?</title><title>The National medical journal of India</title><subject>Adjuvant treatment</subject><subject>Analysis</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Epidermal growth factor</subject><subject>Monoclonal antibodies</subject><subject>Targeted cancer therapy</subject><issn>0970-258X</issn><issn>0970-258X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkc2L1TAUxYsoOI7uXQYEd33mo21e3MgwjDPCgAtn4S7cprfTvGmTmqTzGLf-46Y80fdAssjlcH73wjlF8ZbRTcWo-ECVpCWvt983gjdS0mfF2V_p-dH8sngV447SRrCanRW_vg0-pLJbAiTrHYFutzyCSyQFiGn5uUzQkjRggPmJWEeGLDiCs-0wTDCS--D3aSA9mOQDCWhwXgdezj7aZB-RtAHzJmLAGQzxI7mBSGyKJNkJifETfnpdvOhhjPjmz39e3H2-uru8KW-_Xn-5vLgtTcW3rmSyNxSU7FDWyvSKNrISgJ1A2VQt1C1IBUbyasu4oapt6q7OILaiZT3j4rx4d1g7B_9jwZj0zi_B5Yua11IpXnGp_rnuYURtXe9zEmay0eiLRm55o2glsmvzH1d-HU7WeIe9zfoJ8P4IGBDGNEQ_Lmvo8dRID0YTfIwBez0HO0F40ozqtWm9VqnXKvWh6YxcH5C9H1PO-GFc9hj0hN2D8_sTrjzitKL6tH3xG80Qs3I</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Gogia, Ajay</creator><creator>Mittal, Abhenil</creator><creator>Sharma, Atul</creator><creator>Sagiraju, Hari</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04T</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20210301</creationdate><title>Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?</title><author>Gogia, Ajay ; Mittal, Abhenil ; Sharma, Atul ; Sagiraju, Hari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428n-17fc0a97de759cf906743aed3e764ba5ba79ac724812c09b65d5428eb3b1f123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvant treatment</topic><topic>Analysis</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Epidermal growth factor</topic><topic>Monoclonal antibodies</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gogia, Ajay</creatorcontrib><creatorcontrib>Mittal, Abhenil</creatorcontrib><creatorcontrib>Sharma, Atul</creatorcontrib><creatorcontrib>Sagiraju, Hari</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Health &amp; Medicine</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>The National medical journal of India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gogia, Ajay</au><au>Mittal, Abhenil</au><au>Sharma, Atul</au><au>Sagiraju, Hari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?</atitle><jtitle>The National medical journal of India</jtitle><date>2021-03-01</date><risdate>2021</risdate><volume>34</volume><issue>2</issue><spage>90</spage><epage>91</epage><pages>90-91</pages><issn>0970-258X</issn><eissn>0970-258X</eissn><cop>New Delhi</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/0970-258X.326770</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0970-258X
ispartof The National medical journal of India, 2021-03, Vol.34 (2), p.90-91
issn 0970-258X
0970-258X
language eng
recordid cdi_gale_infotracmisc_A678269043
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adjuvant treatment
Analysis
Antimitotic agents
Antineoplastic agents
Breast cancer
Cancer
Epidermal growth factor
Monoclonal antibodies
Targeted cancer therapy
title Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T09%3A12%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short-duration%20adjuvant%20trastuzumab%20therapy%20in%20human%20epidermal%20growth%20factor%20receptor%202-positive%20breast%20cancers:%20Has%20its%20time%20come?&rft.jtitle=The%20National%20medical%20journal%20of%20India&rft.au=Gogia,%20Ajay&rft.date=2021-03-01&rft.volume=34&rft.issue=2&rft.spage=90&rft.epage=91&rft.pages=90-91&rft.issn=0970-258X&rft.eissn=0970-258X&rft_id=info:doi/10.4103/0970-258X.326770&rft_dat=%3Cgale_proqu%3EA678269043%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579924279&rft_id=info:pmid/&rft_galeid=A678269043&rfr_iscdi=true